PlumX Metrics
Embed PlumX Metrics

LRP2 and DOCK8 are Potential Antigens for mRNA Vaccine Development in Immunologically ‘Cold’ KIRC Tumours

SSRN Electronic Journal
  • 0
    Citations
  • 195
    Usage
  • 0
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Usage
    195
    • Abstract Views
      179
    • Downloads
      16

Article Description

Cancer vaccines based on mRNA are considered a promising strategy and has become a new hot spot in cancer immunotherapy. However, the application to KIRC is not clear. The aims of this study were to identify the potential antigens of KIRC for the development of anti-KIRC mRNA vaccines, and to further differentiate the immune subtypes of KIRC to construct an immune landscape for the selection of appropriate patients for vaccination. Gene expression data and corresponding clinical information were retrieved from the GEO and TCGA databases. The cBioPortal was used to visualise and compare genetic alterations, while GEPIA2 was used to evaluate the prognostic value of selected antigens. The relationship between the infiltration of antigen-presenting cells and the expression of the identified antigen was visualised with TIMER, and consensus clustering analysis was used to determine the immune subtypes. Tumour antigens LRP2 and DOCK8 associated with prognostic and tumour-infiltrating antigen presenting cells were identified in KIRC, and KIRC patients were classified into six immune subtypes. Patients with IS5 and IS6 tumours had an immune ‘hot’ and immunosuppressive phenotype, which was associated with better survival, whereas patients with IS1-4 tumours had an immune ‘cold’ phenotype, which was associated with a higher tumour mutation burden. In addition, the expression of immune checkpoints and immunogenic cell death modulators differed significantly in different immunosubtypes of tumours. This work reveals that LRP2 and DOCK8 are potential KIRC antigens for mRNA vaccine development, and patients with immune subtypes IS1-4 are suitable for vaccination. Funding Information: This work was funded by the National Natural Science Foundation of China (31960139, 31860244, 81502975 and 82002180), the Science and Technology Foundation of Guizhou Province ([2020]1Z016, [2020]1Y087, [2021]431, [2019]1275, 19NSP002; [2019]2823), and the Science and Technology foundation of Guizhou Health Committee (gzwjkj2019-1-037). The grant foundation had no influence in the writing of this manuscript. Declaration of Interests: The authors declare that there is no potential conflict of interest with respect to the research, authorship, and/or publication of this article.

Bibliographic Details

Shichao Zhang; Yu Xiong; Shijing Kang; Chengju Mao; Zhu Zeng; Jian Peng; Yan Ouyang

Elsevier BV

mRNA vaccine; Kidney renal clear cell carcinoma; Tumour antigens; Immune subtypes; Immune landscape

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know